Netherlands· NL-218fee4461ef

Atovaquon Glenmark 750 mg/5 ml suspensie voor oraal gebruik

A atovaquone product containing atovaquon, registered in Netherlands by Glenmark Arzneimittel GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC P01AX06

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about atovaquonAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Atovaquone is registered in 11 of 19 countries.

Countries holding a registration under ATC P01AX06 (atovaquone), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
5 of them publish a price we can compare per daily dose

Search atovaquone products by name

Atovaquone · ATC P01AX06

11 / 19 countries

Belgiumprice
Canada
Denmark
Franceprice
Germany
Netherlands
Norwayprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: ATOVAQUON
Manufacturer: Glenmark Arzneimittel GmbH
Country: Netherlands (NL)
ATC code: P01AX06
ATC class: Atovaquone
Defined daily dose: 1.5 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
119618

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

182 interactions on record for atovaquone.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check atovaquone against other medicines How interaction checks work

Atovaquone · interactions on record

182 records

8 severe
32 moderate
4 minor
133 info

Most severe, free to view

MipomersenC10AX11severe
LomitapideC10AX12severe
EfavirenzJ05AG03severe
PexidartinibL01EX15severe

5 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Atovaquone in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atovaquone products

Authorised across Europe · EMA

The same active substance is authorised in 12 EEA countries. Names it is sold under:

Belgium · Wellvone
Germany · Atovaquon Glenmark, Wellvone
Denmark · Atovaquone Glenmark
Spain · Atovacuona Glenmark, Wellvone
France · Atovaquone Biogaran, Wellvone
United Kingdom (Northern Ireland) · Atovaquone Amarox, Atovaquone Glenmark Pharmaceuticals Europe
Greece · Atovaquone Vocate, Wellvone
Italy · Atovaquone Glenmark, Wellvone
Luxembourg · Wellvone
Norway · Atovaquone Glenmark
Portugal · Atovaquona Kabi, Wellvone
Sweden · Atovaquone Glenmark, Wellvone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/9cf40237-891d-47f1-9bba-238b83d7d050
GET /v1/drugs/9cf40237-891d-47f1-9bba-238b83d7d050?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Suspensie voor oraal gebruik",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h119618_smpc.pdf",
  "strength": null,
  "atc_label": "Atovaquone",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg119618",
  "excipients": [
    "BENZYLALCOHOL (E 1519)",
    "CITROENZUUR 1-WATER (E 330)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "MALTODEXTRINE",
    "POLOXAMEER 188",
    "PROPYLEENGLYCOL (E 1520)",
    "SACCHAROIDE NATRIUM X-WATER (E 954)",
    "TOCOFEROL, DL-ALFA (E 307)",
    "TRINATRIUMCITRAAT 2-WATER (E 331)",
    "TUTTI-FRUTTI SMAAKSTOF",
    "WATER, GEZUIVERD",
    "XANTHAANGOM (E 415)"
  ],
  "substances": [
    "ATOVAQUON"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h119618.pdf",
  "authorised_at": "2018/03/28",
  "procedure_number": "NL/H/3762/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "119618",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about atovaquone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console